Result of Annual General Meeting
Globe Newswire (Tue, 30-Jun 4:30 PM ET)
Globe Newswire (Tue, 30-Jun 8:00 AM ET)
Globe Newswire (Mon, 29-Jun 8:30 AM ET)
Postponement and Re-scheduling of Annual General Meeting
Globe Newswire (Wed, 17-Jun 4:30 PM ET)
Biodexa issues letter to Shareholders
Globe Newswire (Thu, 14-May 8:30 AM ET)
Market Chameleon (Thu, 2-Apr 5:53 AM ET)
Market Chameleon (Thu, 18-Dec 4:37 AM ET)
Market Chameleon (Mon, 3-Nov 3:50 AM ET)
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Biodexa Pharmaceuticals PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol BDRX.
As of July 15, 2026, BDRX stock price declined to $2.24 with 5,980 million shares trading.
BDRX has a beta of 2.36, meaning it tends to be more sensitive to market movements. BDRX has a correlation of 0.08 to the broad based SPY ETF.
BDRX has a market cap of $2.03 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BDRX traded as high as $12,050.00 and as low as $2.10.
BDRX has underperformed the market in the last year with a price return of -95.4% while the SPY ETF gained +22.0%. BDRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -31.1% and -23.0%, respectively, while the SPY returned +9.0% and +1.1%, respectively.
BDRX support price is $2.11 and resistance is $2.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDRX shares will trade within this expected range on the day.
